Targeted chemotherapy: Chronic myelogenous leukemia as a model

Journal of Molecular Medicine

Volumn 80, Issue 4, 2002, Pages 219-232

  Sharifi, Nima ^a,b   Steinman, Richard A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic myelogenous leukemia; Drug development; Signal transduction; Tyrosine kinase inhibitors

Indexed keywords

ALPHA2B INTERFERON; BCR ABL PROTEIN; BUSULFAN; CANERTINIB; CYTARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; INTEGRIN; INTERLEUKIN 3; LEPTOMYCIN B; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; PAXILLIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN; PROTEIN 190; PROTEIN 230; PROTEIN P62; PROTEIN SHC; PROTEIN TYROSINE KINASE; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TETRACYCLINE; TYROSINE KINASE AB1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAV PROTEIN;

AMNESIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; FATIGUE; FLU LIKE SYNDROME; GENETIC MODEL; HUMAN; HYPERPIGMENTATION; LEUKEMIA; LEUKEMIA CELL; LUNG FIBROSIS; MOLECULAR MECHANICS; MUSCLE WEAKNESS; NEUROPATHY; NONHUMAN; PATHOGENESIS; PHILADELPHIA 1 CHROMOSOME; PROGENOTE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; STEM CELL TRANSPLANTATION; WEIGHT REDUCTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MICE;

EID: 0036234952     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-001-0305-3     Document Type: Review

References (159)

1. The molecular biology of chronic myeloid leukemia
2. Chronic myelogenous leukemia: Biology and therapy
3. The biology of chronic myeloid leukemia
4. Chronic myeloid leukemia
5. A minute chromosome in human chronic granulocytic leukemia
6. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia
7. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL)
8. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL
9. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia
10. Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
11. Prognostic discrimination in "good-risk" chronic granulocytic leukemia
12. Analysis and validation of prognostic factors for CML
13. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa
14. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1
15. The genus Cephalotaxus: Source of homoharringtonine and related anti-cancer alkaloids
16. Structures of harringtonine, isoharringtonine, and homoharringtonine
17. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase
18. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
19. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia
20. Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group
21. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
22. Cytarabine increases karyotypic response in alpha-interferon-treated chronic myeloid leukemia patients: Results of a national prospective randomized trial
23. Interferon-alpha combined with cytarabine in chronic myelogenous leukemia - Clinical benefits
24. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma
25. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
26. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
27. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: Its applicability for donor leukocyte transfusions in marrow grafted CML patients
28. Dendritic-cell peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice
29. Current trends in the management of chronic myelogenous leukemia
30. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation
31. Progenitor cell transplantation for chronic myelogenous leukemia
32. Initial therapy for chronic myelogenous leukemia: Playing the odds
33. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia
34. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: A decision analysis
35. Current status of treatment for chronic myelogenous leukemia
36. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lympho-blastic leukemia
37. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia
38. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate
39. Propagation of human blastic myeloid leukemias in the SCID mouse
40. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: An in vivo model of chronic myelogenous leukemia biology
41. Acute leukaemia in bcr/abl transgenic mice
42. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice
43. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
44. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow
45. Bcr-Abl efficiently induces a myelo-proliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia
46. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases
47. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
48. Reversibility of acute B-cell leukaemia induced by BCR-ABL1
49. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
50. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
51. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span
52. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis
53. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site
54. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells
55. Tyrosine phosphorylation of p95Vav in meloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL
56. Tyrosine phosphorylation of p62dok by p210bcr-abl inhibits RasGAP activity
57. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL
58. SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase
59. p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes
60. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity
61. An intramolecular SH3-domain interaction regulates c-Abl activity
62. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways
63. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines
64. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins
65. The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice
66. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein
67. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia
68. Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization
69. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model
70. Bcr: A negative regulator of the Bcr-Abl oncoprotein
71. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein
72. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner
73. Expression of constitutively active Raf-1 in the mitochondria restores anti-apoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant
74. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization
75. Cycling, stressed-out and nervous: Cellular functions of c-Abl
76. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase
77. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway
78. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis
79. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase
80. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes
81. BCR/ABL induces multiple abnormalities of cytoskeletal function
82. Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells
83. p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl
84. Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins
85. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias
86. Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants
87. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: Role in adhesion, invasion, and homing
88. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia
89. Integrin-mediated regulation of hematopoiesis: Do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?
90. Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors
91. Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity
92. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac
93. SHIP1, an SH2 domain containing poly-inositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL
94. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells
95. BCR/ABL confers growth factor independence upon a murine myeloid cell line
96. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner
97. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL
98. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats
99. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients
100. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line
101. Suppression of G-CSF-mediated Stat signalling by IL-3
102. P210 Bcr-Abl interacts with the interleukin 3 receptor beta (c) subunit and constitutively induces its tyrosine phosphorylation
103. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia
104. Growth factor independence and BCR/ABL transformation: Promise and pitfalls of murine model systems and assays
105. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
106. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: Protection is correlated with up regulation of Bcl-xL
107. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
108. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway
109. BCR-ABL accelerates C2-ceramide-induced apoptosis
110. Apoptosis in chronic myeloid leukaemia: Normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids
111. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7
112. Phosphatidyl inositol signaling by BCR/ABL: Opportunities for drug development
113. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors
114. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
115. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
116. ARG tyrosine kinase activity is inhibited by STI571
117. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
118. Sti571: A gene product-targeted therapy for leukemia
119. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
120. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
121. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
122. Acute generalized exanthematous pustulosis associated with sti571 in a patient with chronic myeloid leukemia
123. Cutaneous reactions to STI571
124. Phase II study of STI571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML)
125. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympho-blastic leukemia with the Philadelphia chromosome
126. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents
127. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells
128. STI571: A paradigm for clinical trials of molecularly targeted agents
129. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
130. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
131. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
132. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL (+) leukemic cells to the abl inhibitor STI571
133. Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease
134. Clinical resistance to STI-571 cancer therapy caused by bcr-abl gene mutation or amplification
135. Roots of clinical resistance to STI-571 cancer therapy
136. Roots of clinical resistance to STI-571 cancer therapy
137. Phase I trial of elactocin
138. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service
139. Detection and quantification of residual disease in chronic myelogenous leukemia
140. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class
141. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571
142. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
143. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
144. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing C-KIT (CD117)
145. STI 571, an active drug in metastatic gastrointestinal stromal tumors (GIST) and EORTC phase I study
146. Protein tyrosine kinase inhibitors as novel therapeutic agents
147. From oncogene to drug: Development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents
148. Approval heralds new generation of kinase inhibitors?
149. ZD1839 ('Iressa') as an anti-cancer agent
150. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
151. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
152. Phase 2 Evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck
153. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor
154. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia
155. The multistep nature of cancer
156. Creation of human tumour cells with defined genetic elements
157. The hallmarks of cancer
158. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia
159. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine